hapabapa
- The U.S. FDA on Wednesday granted accelerated approval to AbbVie’s (NYSE:ABBV) Emrelis (telisotuzumab vedotin), an antibody-drug conjugate that is a second-line therapy for non-squamous non-small cell lung cancer with high c-Met protein overexpression.
- Approval was based on results from a